Drug maker Lupin has secured approval from the US health regulator for its generic multiple sclerosis treatment. The company received tentative approval from the USFDA for Siponimod Tablets. This new product will be manufactured at Lupin's Pithampur facility. Siponimod Tablets are bioequivalent to Mayzent tablets and treat relapsing forms of multiple sclerosis in adults.

See Full Page